Yingjia Biosynthesis Completes Tens of Millions of RMB Series A Financing to Accelerate Expansion in Synthetic Biology

VCBeat learned at the earliest opportunity,Sichuan Ingia Biosynthetic Co., Ltd. (hereinafter referred to as “INGIA”) announced the completion of its tens-of-millions-yuan Series A financing, exclusively invested by Addor Capital.This round of financing will be used to accelerate the company's strategic expansion in the field of synthetic biology.

INGIA, established in 2015, is positioned to manufacture natural active ingredients using synthetic biology technologies, such as steviol glycosides, mogrosides, allulose, ferulic acid, and vanillin, with a focus on the food, beverage, and nutritional health products industries. The company is one of the few globally that employs biological methods to produce steviol glycosides (sweeteners) and possesses a leading synthetic biology R&D and production platform.

Natural plant-derived active ingredients have long served as key functional sources in food, pharmaceuticals, health supplements, and daily-use cosmetics. With the growing consumer demand for natural and nutritional products, the application of these natural active ingredients is becoming increasingly widespread across the broader health and wellness industry.

Taking sweeteners as an example, they primarily serve as substitutes for sucrose, glucose, and the like. INGIA’s novel steviol glycoside products, RD and RM, align with the health-oriented concept of natural, low-calorie sweeteners, offering excellent taste and broad application prospects. However, market demand has not yet been fully met due to constraints on supply volume and cost associated with plant-extracted natural products, such as limited raw material availability and low natural content. By leveraging synthetic biology pathways, INGIA continues to reduce production costs and is poised to significantly expand the terminal market application of its products in the future.

“Our core team has over two decades of experience in the research and manufacturing of natural active ingredients. On one hand, we have witnessed robust growth in demand from the broader health and wellness industry; on the other, we have recognized the limitations and development bottlenecks inherent in traditional technological systems. Driven by a vision of innovation and transformation, we established INGIA.”Hua Jun, Chairman of INGIAstated,Over the past six years, the company has deployed dozens of self-developed products for health-related sectors, including pharmaceuticals, food and beverages, and dietary supplements. More than five new products are scheduled to launch in the next two years.

“Guided by the development philosophy of ‘independent intellectual property rights, low-carbon and green practices, a focus on user experience, and zero quality defects,’ and backed by products with excellent cost-performance ratios, the company has earned growing trust from customers in the market. We have established strong business relationships with numerous renowned enterprises both domestically and internationally, and are now on a fast track for growth. We extend our gratitude to Yida Capital for its support, and we look forward to a vibrant and fruitful future for China’s synthetic biology industry.”

Xue Yi, Partner at Yida Capital“Synthetic biology is a key focus area for Yida Capital, where we have already made a series of investments. The biosynthesis of natural active ingredients is one of the most promising sub-sectors within synthetic biology, and our investment in INGIA represents Yida Capital’s strategic positioning in this specific niche.”

Xue Yi believes that INGIA focuses on the biosynthesis of natural active ingredients. Its industrial direction aligns with the concept of green manufacturing advocated by the state. The company boasts a highly capable and well-balanced core team, comprehensively covering all key stages, including upstream strain R&D, midstream large-scale manufacturing, and downstream market expansion.

“The Chairman of INGIA has deep expertise in the field of natural products, abundant industrial resources, and a unique vision for the industry’s development direction. Professor Wang Yong, the company’s Chief Scientist, has conducted pioneering work and achieved significant breakthroughs in the biosynthesis of plant-derived natural active ingredients, particularly in representative sweeteners such as steviol glycosides. The company’s technical team possesses profound expertise and practical industrial experience in strain construction and optimization, large-scale fermentation control, and separation and purification. We believe that as the company’s strategic layout is gradually implemented, INGIA is poised to become a practitioner in the application of synthetic biology technologies and a leader in the biosynthetic development of natural active ingredients,” said Xue Yi.